All News

If you really break it down, there are only two emotions that consume the world and all its living beings: love and fear.

Ed's weakened immune system continues to haunt him.

At the 2016 ASCO Annual Meeting, the vice president called for a commitment to team science, improved patient access to clinical trials, and announced a new cancer genomic and clinical data-sharing resource.

Aggressive end-of-life care is often harmful to patients and their families, yet is still so widely used.

In the longest follow-up of an anti-PD-1 immunotherapy in RCC, about one-third of the patients treated with single-agent Opdivo are still alive four and five years later.

Women are reducing their risk of recurrence by extending their adjuvant therapy with an aromatase inhibitor (AI) to 10 years after treatment for their early-stage HR-positive breast cancer.

Tecentriq is showing reduction in tumor size for patients with metastatic urothelial carcinoma, according to a phase 2 study.

Breast cancer can bring the surprise of lymphedema to the unsuspecting, uniformed patient.

People across the nation are participating in the Metastatic Breast Cancer (MBC) Project to help researchers steer the approach in fighting the disease.

Treating patients based on the presence of molecular abnormalities regardless of tumor type proved to be a promising strategy in an ongoing phase 2a basket study.

Though more research still needs to be done, potential for liquid biopsies was shown in a study involving 15,000 patients who represented a multitude of cancer types.

This study was presented in conjunction with the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), a gathering of over 30,000 oncology professionals in Chicago.

Women who received intraperitoneal chemotherapy after surgery for ovarian cancer had a reduced amount of disease progression when compared with those who received chemotherapy via IV.

Patients with heavily pretreated relapsed/refractory multiple myeloma showed increased progression-free survival and overall survival rates with isatuximab.

In a phase 3 trial, five-year overall survival was nearly doubled when capecitabine was added to gemcitabine for patients with pancreatic cancer.

Recent findings may make way for a less expensive treatment option for patients with metastatic breast cancer.

What are the next steps for immunotherapy in RCC? CURE spoke with Mark Ball to find out.

Patients with early-stage prostate cancer may be able to shorten their radiation time, thanks to the results of a recent study conducted by the Duke Cancer Institute.

Surgery is still the most promising treatment option for many patients with melanoma, says Giorgos C. Karakousis.

Patients with multiple myeloma live longer without their disease progressing if they get a stem cell transplant, compared with patients who received chemotherapy alone.

Checkpoint blockade immunotherapies like Keytruda are increasing the OS rates for patients with advanced melanoma.

Diet and exercise play a big role in health, especially when it comes to cancer, Katrina Claghorn says.

Melanoma cancer survivor is grateful and feels like she discovered that she is allergic to air.

A side effect of chemotherapy is a weakened immune system, which brings on unwanted occurrences.

The role of radiation continues to change for patients with breast cancer, especially for those over the age of 70, for whom radiation might not be the best option.

Immunotherapy is showing promise for treatment of head and neck cancer who progress after chemotherapy, though there is still a long way to go, says Robert Ferris.

Patients' confidence that they can manage problems related to their colorectal cancer can have a great impact on their recovery, according to a recent study.

Summer presents many challenges for breast cancer survivors, especially those who've experienced mastectomies.